These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 14768175

  • 1. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
    Modelska-Ziółkiewicz A, Gembicki M, Bednarek J, Sowiński J.
    Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
    [Abstract] [Full Text] [Related]

  • 2. [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter].
    Modelska-Ziółkiewicz A, Gembicki M, Sowiński J.
    Pol Arch Med Wewn; 2003 May; 109(5):463-8. PubMed ID: 14768174
    [Abstract] [Full Text] [Related]

  • 3. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
    De Bellis A, Bizzarro A, Gattoni A, Romano C, Di Martino S, Sinisi AA, Abbadessa S, Bellastella A.
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
    [Abstract] [Full Text] [Related]

  • 4. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy.
    Wakelkamp IM, Gerding MN, van der Meer JW, Prummel MF, Wiersinga WM.
    Clin Exp Immunol; 2002 Feb; 127(2):316-20. PubMed ID: 11876756
    [Abstract] [Full Text] [Related]

  • 5. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A, Di Martino S, Fiordelisi F, Muccitelli VI, Sinisi AA, Abbate GF, Gargano D, Bellastella A, Bizzarro A.
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [Abstract] [Full Text] [Related]

  • 6. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy].
    Kulig G, Pilarska K, Kulig J, Krzyzanowska-Swiniarska B, Robaczyk M, Baraniak A.
    Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.
    Heufelder AE, Bahn RS.
    Clin Exp Immunol; 1993 May; 92(2):296-302. PubMed ID: 8097976
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids.
    Myśliwiec J, Kretowski A, Szelachowska M, Topolska J, Mikita A, Kinalska I.
    Immunol Lett; 2001 Oct 01; 78(3):123-6. PubMed ID: 11578685
    [Abstract] [Full Text] [Related]

  • 11. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A.
    Clin Endocrinol (Oxf); 2005 Jan 01; 62(1):24-9. PubMed ID: 15638866
    [Abstract] [Full Text] [Related]

  • 12. The blood concentration of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with active thyroid-associated orbitopathy before and after methylprednisolone treatment.
    Nowak M, Wielkoszyński T, Kos-Kudła B, Marek B, Karpe J, Kajdaniuk D, Siemińska L, Głogowska-Szelag J, Foltyn W, Strzelczyk J, Nowak K.
    Endokrynol Pol; 2007 Jan 01; 58(6):487-91. PubMed ID: 18205104
    [Abstract] [Full Text] [Related]

  • 13. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy.
    Ozata M, Bolu E, Sengül A, Altinsoy HI, Turan M, Corakci A, Hacibektasoglu A, Gundogan MA.
    Endocr J; 1996 Oct 01; 43(5):517-25. PubMed ID: 8980891
    [Abstract] [Full Text] [Related]

  • 14. Circulating levels of soluble adhesion molecules in patients with ANCA-associated vasculitis.
    Di Lorenzo G, Pacor ML, Mansueto P, Lo Bianco C, Di Natale E, Rapisarda F, Pellitteri ME, Ditta V, Gioè A, Giammarresi G, Rini GB, Li Vecchi M.
    J Nephrol; 2004 Oct 01; 17(6):800-7. PubMed ID: 15593054
    [Abstract] [Full Text] [Related]

  • 15. [Assessment of soluble E selectin levels in patients with Graves' disease and thyroid orbitopathy].
    Kulig G, Pilarska K, Kulig J, Robaczyk M, Gromniak E.
    Przegl Lek; 2004 Oct 01; 61(12):1314-8. PubMed ID: 15850320
    [Abstract] [Full Text] [Related]

  • 16. Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy.
    Nowak M, Wielkoszyński T, Marek B, Kos-Kudła B, Swietochowska E, Siemińska L, Kajdaniuk D, Głogowska-Szelag J, Nowak K.
    Clin Exp Med; 2008 Sep 01; 8(3):159-64. PubMed ID: 18791689
    [Abstract] [Full Text] [Related]

  • 17. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy].
    Myśliwiec J, Kretowski A, Topolska J, Stepień A, Kinalska I.
    Pol Arch Med Wewn; 2002 Aug 01; 108(2):739-44. PubMed ID: 12476893
    [Abstract] [Full Text] [Related]

  • 18. Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients.
    Boldt J, Muller M, Kuhn D, Linke LC, Hempelmann G.
    Intensive Care Med; 1996 Feb 01; 22(2):122-8. PubMed ID: 8857119
    [Abstract] [Full Text] [Related]

  • 19. Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.
    Smallridge RC, Tsokos GC, Burman KD, Porter L, Cranston T, Sfikakis PP, Solomon BL.
    Clin Diagn Lab Immunol; 1997 Sep 01; 4(5):583-6. PubMed ID: 9302209
    [Abstract] [Full Text] [Related]

  • 20. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
    Ozata M, Bolu E, Sengul A, Tasar M, Beyhan Z, Corakci A, Gundogan MA.
    Thyroid; 1996 Aug 01; 6(4):283-8. PubMed ID: 8875747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.